Medtronic kicks off study for pain pump

Medtronic (NYSE:MDT) said today that it enrolled the first patient in a study to assess the use of its SynchroMed II intrathecal drug delivery system as an alternative to oral opioids.
The 100-patient Embrace TDD study is slated to follow patients who have weaned off all oral opioids, in the hopes of positioning the SynchroMed II pump as a viable alternative for people with chronic intractable non-malignant primary back pain.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic kicks off study for pain pump appeared first on MassDevice.

Source: Mass Device - January 17, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Pain Management Pharmaceuticals Wall Street Beat Medtronic Source Type: news